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Summary
BACKGROUND: Campylobacteriosis and salmonellosis
are important foodborne diseases in Europe, including
in Switzerland. In 2014, notification rates for Switzerland
were 92.9 per 100 000 population for campylobacteriosis
and 15.2 per 100 000 population for salmonellosis. These
notification rates originate from laboratory-based surveil-
lance whereby positive test results are reported to the Na-
tional Notification System for Infectious Diseases. Conse-
quently, notification rates do not directly correspond to the
disease burden among the population as the number of
positive tests depends on patients’ healthcare-seeking be-
haviour, stool sampling rates and other factors.
METHODS: We assessed laboratory positivity rates (pro-
portion of positive tests among all tests performed) of
diagnostic tests for Campylobacter and Salmonella from
five private laboratories in Switzerland between 2003 and
2012. We analysed demographic characteristics, temporal
and spatial distribution of test numbers and positivity rates.
Predictors for a positive test and disease seasonality were
assessed with logistic regression analyses.
RESULTS: A total of 135 122 (13 095 positive) Campy-
lobacter tests and 136 997 (2832 positive) Salmonella
tests were obtained with positive tests corresponding to
20.4% and 17.2% of notified campylobacteriosis and sal-
monellosis cases, respectively. The number of tests con-
ducted annually increased for both pathogens by 51%
from 2003 to 2012. Annual positivity rates of Campylobac-
ter increased from 7.6 to 11.1% and rates of Salmonella
decreased from 2.7 to 1.5%. The largest increases in an-
nual Campylobacter positivity rates were observed for pa-
tients older than 85 years (+193.7%), followed by children
aged 5–9 years (+131.9%). Positivity rates and test num-
bers for both diseases by month or calendar week showed
a distinct seasonality, with peak rates for Salmonella oc-
curring in autumn and for Campylobacter in summer and
at the turn of the year. These findings were independent of
patients’ age and sex.
CONCLUSIONS: Both positivity rates and notification
rates showed increasing trends for Campylobacter and
decreasing trends for Salmonella, suggesting that these
trends reflect changes in disease epidemiology at popu-
lation level. The continuous assessment of positivity rates
remains important to appropriately interpret changes ob-
served in the notification system especially considering
the increasing use of multiplex polymerase chain reaction
test panels where multiple pathogens are tested simulta-
neously.
Key words: Campylobacter, Salmonella, disease surveil-
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Introduction
Human campylobacteriosis and salmonellosis are the most
frequently reported foodborne bacterial infections in Eu-
rope. In 2014, notification rates in the European Union
(EU) were 71.0 cases per 100 000 population (correspond-
ing to approximately 236 900 cases) for campylobacterio-
sis and 23.4 cases per 100 000 population (approximate-
ly 88 700 cases) for salmonellosis [1]. In the same year,
in Switzerland, the notification rate for Campylobacter in-
fections was 92.9 cases per 100 000 population (approxi-
mately 7600 cases) and 15.2 cases per 100 000 population
(approximately 1200 cases) for Salmonella infections [1].
During the mid-1990s, the annual number of notified hu-
man Campylobacter infections surpassed that of Salmonel-
la infections in Switzerland [2]. This was owing to a re-
duction of human salmonellosis following the introduction
of control measures in the egg and poultry industry, such
as mandatory screening of layer hens, in the early 1990s
[2]. So far, similar control measures for Campylobacter are
lacking and campylobacteriosis is currently the most fre-
quently notified foodborne disease in Switzerland [2].
In Switzerland, notifiable diseases are monitored by the
Federal Office of Public Health (FOPH) through the Na-
tional Notification System for Infectious Diseases
(NNSID) [3, 4]. Laboratory-based surveillance of Campy-
lobacter and Salmonella infections, as defined by the Epi-
demics Act of 1970 and its related ordinances, captured
only those cases that tested positive [5–7]. Since the im-
plementation of the new Epidemics Act at the beginning
of 2016, the total number of tests conducted for these two
pathogens, including the number of positive results, must
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be reported annually as aggregated numbers, stratified by
month and test method [4, 8]. Hence, denominator data
to help draw inferences from surveillance data about the
epidemiological situation in the community have not been
collected so far. The number of stool tests performed de-
pends on the healthcare-seeking behaviour of patients with
diarrhoea and the stool sampling rate of treating physicians
[9–11]. As not all individuals affected by acute gastroen-
teritis seek medical care or have a stool sample examined
for enteric pathogens, there are likely to be many unde-
tected (at community level) and unreported (at healthcare
level) campylobacteriosis and salmonellosis cases [12, 13].
Hence, changes in notification rates do not necessarily re-
flect an epidemiological trend, but could be attributable to
changes in healthcare-seeking behaviour or stool sampling
rates. A more informed interpretation of surveillance da-
ta is made possible by calculating positivity rates (propor-
tion of positive tests among all tests performed). Because
positivity rate calculations also consider denominator data,
they adjust for the number of tests [14, 15]. We analysed
laboratory data for stool tests performed for Campylobac-
ter spp. and Salmonella spp. by Swiss diagnostic labora-
tories over a 10-year period to better interpret the trends
of campylobacteriosis and salmonellosis case notifications
seen in the NNSID.
Materials and methods
Selection of diagnostic laboratories
The study aimed to include private diagnostic laboratories
from all geographical and linguistic regions of Switzerland
to reach an optimal representation of the campylobacterio-
sis cases reported to the NNSID between 2003 and 2012.
Eleven private diagnostic laboratories, each reporting more
than 1000 campylobacteriosis cases during that decade,
were contacted and invited to provide data for the study.
The case-based laboratory data requested comprised pa-
tients’ demographic characteristics (sex, age, canton of res-
idence, personal identification code assigned by labora-
tory) and test characteristics (pathogen tested, test result,
date of test, test method) on all Campylobacter and Salmo-
nella tests performed between 2003 and 2012.
Analysis of positivity rates
Datasets from individual laboratories were transformed
uniformly, merged and analysed with STATA™ Version
13.1 (Stata Corporation; College Station, TX, USA). First-
ly, double entries, repeated tests and tests for patients with-
out Swiss residency were excluded. The following rules –
based on disease durations and durations of organism ex-
cretion [16] – were applied to identify and exclude repeat-
ed tests: (i) control or follow-up tests, irrespective of re-
sult, following a positive result within 42 days for both,
Campylobacter and Salmonella; (ii) negative tests follow-
ing a negative result within 10 days (Campylobacter) or
21 days (Salmonella); and (iii) negative tests followed by a
positive result within 10 days (Campylobacter) or 21 days
(Salmonella). The patient population was characterised by
sex, age, diagnostic laboratory, test year and residence by
greater region (corresponding to the Nomenclature of
Units for Territorial Statistics (NUTS) 2 level [17]). Age
groups for statistical analyses were predefined. Residence
by greater region was based on the patients’ canton of res-
idence (NUTS 3 level). Descriptive analysis of positivi-
ty rates – defined as positive tests divided by total tests
performed – and exploratory logistic regression analyses
of predictors for and seasonality of positive tests were
performed. Characteristics of laboratory-confirmed cases
of campylobacteriosis and salmonellosis were additionally
compared with national surveillance data. Time trends of
annual positivity rates were investigated using stratifica-
tion and direct standardisation for age groups and sex.
Thus, the population of individuals tested from 2003 to
2012 was used as the reference population. The seasonality
of monthly and weekly positivity rates was assessed by
calculating positivity rates from laboratory data from the
whole observation period pooled by month or calendar
week.
Univariable and multivariable regression models
In a first step, univariable logistic regression analyses were
performed to estimate the effect of sex, age group, labo-
ratory, residence by greater region, test week, test month
and test year on the test result. Afterwards, a multivariable
logistic regression model estimated the unconfounded ef-
fects of sex, age groups, laboratories, residence by greater
region and test year on the test result. The effect of season-
al within-year variations on test outcome were investigat-
ed with a second multivariable logistic regression model
including test month and adjustments for sex, age groups,
laboratories, residence by greater region and test year. For
this model, the test month with a positivity rate closest to
the mean positivity rate of all test months was used as a
baseline and test year was introduced as a random effect.
The significance of variables in the multivariable models
was assessed by likelihood ratio tests and the category of
each variable with the most observations (except for test
month) was used as a baseline to make the model more ro-
bust. Patients with missing information on the canton of
residence were assigned the greater region of their corre-
sponding laboratory.
Ethics statement
The study was approved by the local ethical committee
“Ethikkommission Nordwest- und Zentralschweiz” [Ethi-
cal committee of Northwestern and Central Switzerland]
(No.: EKNZ:2014-164).
Results
Exclusion of test results and representativeness
Eight laboratories agreed to participate in the study and
five of them provided complete data for Campylobacter
and Salmonella tests performed as requested. The eight
laboratories conducted a total of 196 307 Campylobacter
tests (17 694 positive) and 199 062 Salmonella tests (4163
positive) between 2003 and 2012. Excluding data from the
three laboratories with incomplete data led to the exclusion
of 43 530 (3345 positive) Campylobacter tests and 45 114
(640 positive) Salmonella tests. Among the remaining lab-
oratories (A to E), removal of double entries, repeated tests
and tests of non-Swiss residents led to the exclusion of
a further 17 211 (1245 positive) Campylobacter tests and
16 499 (689 positive) Salmonella tests. Additionally, we
excluded 444 (9 positive) Campylobacter tests and 452 (2
positive) Salmonella tests because of missing information
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on sex and/or age. In the detailed analysis, 135 122 (13 095
positive) Campylobacter tests and 136 997 (2832 positive)
Salmonella tests were included. Culture-based test meth-
ods accounted for 98.7% of all Campylobacter and Sal-
monella tests conducted, and polymerase chain reaction
(PCR) tests accounted for 1.3%. Positive tests included in
the analysis corresponded to 20.4% and 17.2% of campy-
lobacteriosis and salmonellosis cases, respectively, regis-
tered in the NNSID between 2003 and 2012 (tables 1 and
2).
Characteristics of the patient population and overview
of tests performed
The annual number of tests performed increased by 51.1%
from 2003 to 2012 (11 674 to 17 641 tests) for Campy-
lobacter and by 50.7% (11 842 to 17 842 tests) for Salmo-
nella (fig. 1). For both diseases, annual test numbers de-
creased by at least 6% for the age groups <5 years and
5–9 years, and increased by at least 31% in the older
age groups. The median age of patients tested for Campy-
lobacter was 42 years (range <1–108 years) and 41 years
(range: <1–108 years) for Salmonella. Patients’ age dif-
fered significantly between laboratories and test years for
both pathogens (Kruskal-Wallis test: p <0.01 for all four
tests). Slightly more tests were conducted among females
than among males for Campylobacter (54.8%) and for Sal-
monella (54.3%). The sex ratio differed between laborato-
ries and test years for both pathogens (chi-square test: p
<0.01 for all four tests). The patients’ residence by greater
region was associated with the geographical location of the
laboratory that performed the test.
Annual positivity rates overall and by laboratory
Annual Campylobacter positivity rates standardised for
age and sex increased by 46.1% from 2003 (7.6%) to 2012
(11.1%) (fig. 2). Annual standardised Salmonella positivi-
ty rates showed an inverse trend and decreased by 44.4%
from 2003 (2.7%) to 2012 (1.5%). Campylobacter posi-
tivity rates stratified by laboratory (and standardised for
age and sex) showed similar annual trends (supplementary
fig. S1 in appendix 1). The annual positivity rates of lab-
oratory C were remarkably lower throughout the investi-
gated period compared with other laboratories. Laborato-
Table 1: Comparison of campylobacteriosis cases from laboratory data with cases registered in the National Notification System for Infectious Diseases by test year, Switzer-
land, 2003–2012.
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Proportion of NNSID cases reported
by study laboratories in %
16.7 16.7 17.6 20.4 21.8 21.1 21.4 21.0 21.1 23.0
Proportion of NNSID cases by
greater region reported by study lab-
oratories in %
Lake Geneva 1.5 2.5 2.0 3.5 3.0 3.0 4.0 4.0 3.5 4.0
Espace Mittelland 17.0 17.0 18.5 26.0 27.0 27.0 28.5 29.0 28.0 28.5
Northwestern Switzerland 26.0 22.5 23.0 25.0 27.5 26.0 27.0 25.0 27.0 33.0
Zurich 24.0 27.0 28.0 29.0 29.5 29.0 23.0 28.0 25.0 26.5
Eastern Switzerland 15.0 18.0 18.0 16.5 18.5 20.5 22.0 19.5 23.0 24.0
Central Switzerland 8.0 7.5 8.5 6.5 7.0 6.5 6.0 7.0 6.5 8.0
Ticino 45.5 47.0 44.0 63.0 69.5 54.5 60.0 52.5 57.0 58.0
Proportion of males in %
Laboratories 56.6 55.4 53.5 57.7 55.2 53.7 55.8 53.0 54.6 54.9
NNSID 55.4 54.8 54.8 55.0 53.5 53.5 53.6 53.8 53.7 54.0
Median age in years
Laboratories 34 34 34 35 35 36 37 37 39 36
NNSID 32 33 34 34 35 35 35 37 36 36
Table 2: Comparison of salmonellosis cases from laboratory data with cases registered in the National Notification System for Infectious Diseases by test year, Switzerland,
2003–2012.
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Proportion of NNSID cases reported
by study laboratories in %
15.6 15.9 15.7 16.7 17.7 16.4 17.4 19.0 21.0 19.8
Proportion of NNSID cases by greater
region reported by study laboratories
in %
Lake Geneva 0.5 2.5 2.0 3.0 4.5 4.0 2.0 1.0 3.0 1.0
Espace Mittelland 14.5 18.0 14.0 19.0 19.5 19.0 18.5 20.5 28.5 21.0
Northwestern Switzerland 20.0 21.0 21.0 24.0 22.5 17.5 23.0 23.0 19.0 29.5
Zurich 19.0 17.5 18.0 22.0 23.5 21.5 23.0 25.0 14.0 24.5
Eastern Switzerland 9.5 11.0 16.5 12.5 14.5 14.0 17.0 23.0 19.5 18.5
Central Switzerland 6.0 6.5 3.5 7.5 3.5 4.5 4.5 12.0 3.0 10.5
Ticino 49.5 51.0 43.5 48.5 46.0 49.5 45.0 47.0 72.5 48.5
Proportion of males in %
Laboratories 53.2 53.4 56.0 58.8 57.1 55.0 57.9 52.3 49.6 52.2
NNSID 52.1 49.6 53.1 56.2 54.3 51.4 53.0 52.4 51.2 52.5
Median age in years
Laboratories 18 23 23 25 30 28 29 25 24 25
NNSID 25 25 26 25 27 28 27 27 28 26
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ry-specific Campylobacter positivity rates ranged from 3.8
to 9.4% in 2003 and continuously increased to 7.0–13.2%
in 2012. For Salmonella, annual positivity rates by labora-
tory differed only slightly between laboratories; the high-
est rates were observed for laboratory C, with two distinct
peaks in 2007 and 2011. Overall, a decreasing trend was
observed; positivity rates dropped from 2.1–3.8% in 2003
to 1.2–2.7% in 2012.
Annual positivity rates by sex and age groups
The annual Campylobacter positivity rates for males and
females increased by 43.6% (from 9.4 to 13.5%) and by
45.2% (from 6.2 to 9.0%), respectively, from 2003 to 2012.
In the same decade, annual Campylobacter positivity rates
Figure 1: Number of stool tests for Campylobacter (a) and Salmo-
nella (b) by sex in five diagnostic laboratories, Switzerland,
2003–2012.
Figure 2: National Notification System for Infectious Diseases
(NNSID) notification rates and positivity rates (standardised for
age and sex) of Campylobacter and Salmonella, Switzerland,
2003-2012.NNSID data provided by the Federal Office of Public
Health, Bern, Switzerland
by age group increased for all age groups. The largest in-
crease was observed for the age group ≥85 years (193.7%)
followed by the 5–9-year-olds (131.9%). Compared with
2003, annual Campylobacter positivity rates of sex-specif-
ic age groups were higher in 2012, except for females in
the age group 10–14 years (fig. 3a). Annual Campylobac-
ter positivity rates were generally higher for males than
for females over the entire observation period. For males
and females in the age groups <5 years, 5–9 years and ≥85
years, similar annual Campylobacter positivity rates were
observed at the beginning of the decade but rates were later
slightly higher for males in the age group ≥85 years and for
females in the age groups <5 years and 5–9 years.
Annual Salmonella positivity rates decreased from 3.3% to
1.6% (−51.5%) for males and from 2.5% to 1.2% (−52.0%)
for females between 2003 and 2012. Annual positivity
rates decreased for all age groups between 2003 and 2012
except for the age group 20–24 years, for which the rate re-
mained rather stable. The largest relative decrease of pos-
itivity rates was observed for the age groups 10–14 years
and ≥85 years, where rates decreased from 10.5 to 3.7%
(−64.8%) and from 0.8 to 0.2% (−75.0%), respectively.
Sex-specific Salmonella positivity rates were similar or
slightly higher for males compared to females in all age
groups although for some age groups, positivity rates var-
ied strongly between years (fig. 3b).
Seasonal trends in stool sampling and positivity rates
The number of tests performed for Campylobacter and Sal-
monella started to increase in spring (fig. 4 panels a and
c, fig. 5 panels a and c). Test numbers peaked in late Au-
gust (calendar week 34) after a brief and strong temporary
decline at the beginning of the month (calendar week 31).
Afterwards, the number of tests decreased until the end of
the year. Monthly test numbers were lowest in February
for Campylobacter and Salmonella, even though calendar
week 1 was the week with the fewest tests performed.
After a continuous increase during spring, monthly
Campylobacter positivity rates peaked during summer
months, with the highest monthly rate occurring in July
(13.8%) (fig. 4 panels b and d). Likewise, monthly Salmo-
nella positivity rates started increasing during the spring.
They peaked twice, first in late summer (August) and then
in the autumn, with the highest rate occurring in October
(3.1%) (fig. 5 panels b and d). The highest weekly positiv-
ity rate for Campylobacter (17.3%) was in calendar week
1 (January), whereas the peak of weekly Salmonella posi-
tivity rates (3.5%) was in calendar week 43 (October). The
lowest monthly positivity rates for Campylobacter and Sal-
monella were in February (5.3%) and March (1.1%), re-
spectively. The seasonal trends of Campylobacter and Sal-
monella positivity rates were also observable for sex- and
age-specific positivity rates although less pronounced in
certain groups.
Regression analyses
In the univariable regression analyses, sex, age, laboratory,
residence by greater region, test week, test month and test
year all had a significant effect on the test result for both
diseases. The multivariable regression analysis of predic-
tors for a positive Campylobacter test showed higher odds
of a positive test for males than for females (odds ra-
tio [OR] 1.53, 95% confidence interval [CI] 1.47–1.59)
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(supplementary table S1, appendix 1). Patients in the age
groups 15–19 years and 20–24 years had higher odds for a
positive test outcome compared with the age group 25–44
years, whereas patients of other age groups had reduced
odds. The patients’ place of residence by greater region
had similar odds for a positive test, except for patients from
Figure 3: Annual positivity rates of Campylobacter (a) and Salmonella (b) by age group and sex, Switzerland, 2003-2012.
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Figure 4: Seasonality of Campylobacter tests and positivity rates (pooled over study period) per month and calendar week, Switzerland,
2003–2012.
Figure 5: Seasonality of Salmonella tests and positivity rates (pooled over study period) per month and calendar week, Switzerland,
2003–2012.
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the Ticino region (OR 0.44, 95% CI 0.38–0.52). From
2003 to 2008, the odds increased continuously and de-
creased slightly between 2009 and 2011 compared with
2012.
The regression model for seasonal within-year variations
showed that the odds for a positive Campylobacter test was
highest in July (OR 1.52, 95% CI 1.40–1.65) and lowest
in February (OR 0.55, 95% CI 0.49–0.61) compared with
May, which had a positivity rate closest to the monthly av-
erage (supplementary table S2). Significantly higher odds
were also observed for June (OR 1.38, 95% CI 1.26–1.50)
and August (OR 1.24, 95% CI 1.14–1.35) compared with
May.
In the multivariable regression model for Salmonella,
males had higher odds (OR 1.30, 95% CI 1.21–1.40) of a
positive test than females (supplementary table S3). The
odds of a positive test outcome increased threefold for the
age groups <5 years, 5–9 years and 10–14 years com-
pared with the age group 25–44 years. Greater region was
no longer significantly associated with the outcome in the
multivariable regression model. The odds of a positive test
outcome steadily decreased during the study period com-
pared with 2012. In the second multivariable model for
seasonality, the highest odds of a positive Salmonella test
were observed in October (OR 1.61, 95% CI 1.36–1.90)
and August (OR 1.44, 95% CI 1.23–1.70) compared with
November (supplementary table S4). The lowest odds
(compared with November) were observed in March (OR
0.55, 95% C: 0.44–0.68) and February (OR 0.57, 95% CI
0.46–0.72).
Discussion
Annual Campylobacter positivity rates standardised for
age and sex increased from 2003 to 2012, whereas stan-
dardised Salmonella positivity rates decreased. During the
same time period, campylobacteriosis notification rates in-
creased from 72.7 to 105.5 notifications per 100 000 pop-
ulation, whereas salmonellosis notification rates decreased
from 29.8 to 15.4 per 100 000 population. Campylobacter
positivity rates were generally higher for males than fe-
males in all age groups. Monthly and weekly Campylobac-
ter positivity rates showed a distinct seasonality, with a
peak during the summer months and again at the beginning
of the year, which was independent of sex and age group.
Salmonella positivity rates showed a similar seasonality,
but peaked in autumn. Annual Salmonella positivity rates
were similar or slightly higher for males than for females,
with the highest rates observed in the younger age groups,
<5, 5–9 and 10–14 years. The observed seasonality and an-
nual trends of positivity rates for both pathogens are con-
gruent with reports from other countries [14, 18].
Annual positivity rates in relation to NNSID notifica-
tion rates
Annual positivity rates of Campylobacter and Salmonella
standardised for age and sex and annual NNSID notifi-
cation rates showed similar trends. Multiple testing, data
duplication or simultaneous testing of several pathogens
could potentially affect both numerator and denominator
data in different ways. However, similar trends were ob-
served for the standardised annual positivity rates present-
ed here and for the crude, non-standardised positivity rates
calculated from raw data from all eight laboratories includ-
ed in the study (supplementary fig. S2, appendix 1).
The stool test data analysed for this study originated main-
ly from culture-based test methods, which used to be the
standard diagnostic method for detecting Campylobacter
and Salmonella. Campylobacter, Salmonella and Shigella
are often tested simultaneously [19]. In terms of relative
frequency, more positive Salmonella tests (18.9%) than
positive Campylobacter tests (8.4%) were excluded,
whereas the proportion of excluded duplicate and repeated
tests was similar for negative Campylobacter and Salmo-
nella tests (11.2 vs 10.2%). The proportion of negative Sal-
monella tests excluded dropped only slightly from 10.2 to
9.4% when the same time span used for excluding negative
Campylobacter tests was applied. Hence, only laboratory-
confirmed campylobacteriosis and salmonellosis patients
differ with regard to repeated testing. In summary, reduc-
ing the number of tests per patient and disease episode to
one test result is crucial for an accurate calculation of posi-
tivity rates whereas the temporal trend of positivity rates is
not considerably affected.
The relative increase in standardised annual Campylobac-
ter positivity rates (+46.1%) and the relative decrease in
standardised annual Salmonella positivity rates between
2003 and 2012 (−44.4%) are close to the increase in no-
tification rates of Campylobacter (+45.0%) and the de-
crease in notification rates of Salmonella (−48.4%). During
the same time period, the number of tests performed for
Campylobacter and Salmonella increased by around 51%.
The proportion of cases diagnosed by participating lab-
oratories among NNSID case notifications increased by
37.7% for campylobacteriosis and by 26.9% for salmonel-
losis over the study period.
The observed increase of test numbers in our study was
partially due to a single laboratory (laboratory A), where
the number of tests increased 3.5 times for Campylobacter
and 3.8 times for Salmonella between 2003 and 2012. This
laboratory was founded a few years before the study peri-
od. For the remaining laboratories (B, C, D, E), a smaller
increase of 32.0% for Campylobacter tests and of 29.0%
for Salmonella tests was observed. An increase in testing
frequency has also been observed in other European coun-
tries [14, 20], except in the Netherlands, where testing fre-
quency remained rather stable [21]. Testing frequencies are
largely influenced by physicians’ stool sampling behaviour
and patients’ healthcare-seeking behaviour [14, 22–25]. It
is also possible that laboratories in the study increased their
market shares.
The increase of Campylobacter notification rates is prob-
ably due to a combination of increasing test numbers and
an upward epidemiological trend in the population, as sug-
gested by the increase in positivity rates. The decrease of
Salmonella notification rates presumably reflects an epi-
demiological trend in the population, as the notification
rate decreased at the same time that testing frequency in-
creased. The increase of campylobacteriosis cases in the
population, together with the co-testing of Salmonella and
Campylobacter, is probably responsible for the increase of
Salmonella test numbers.
In summary, notification rates are influenced by both epi-
demiological trends in the population and test numbers.
More infections in the population will lead to higher noti-
fication rates and fewer infections will lead to lower noti-
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fication rates. On the other hand, increasing test numbers
can lead to the detection of more cases in the population,
i.e., higher notification rates without necessarily reflecting
an increase in disease frequency. Consequently, an ob-
served increase in notification rates does not necessarily
represent an actual increase of disease frequency in the
population. A change in test numbers can be due to a num-
ber of factors such as changes in the prevalence of risk fac-
tors leading to testing, altered healthcare-seeking behav-
iour, and changes in physicians’ testing practices, human
susceptibility, and pathogenicity. Assessing the interplay of
notification rates and test numbers by positivity rates pro-
vides more insights into the epidemiological situation in
the population than one of these measures alone. Neverthe-
less, understanding underlying reasons for changes in one
of these measures requires further investigation.
Positivity rates in relation to age and sex
A remarkable increase in Campylobacter positivity rates
was observed for the age groups 5–9 years and ≥85 years
(+131.9% and +193.7%). Test numbers for the age group
5–9 years decreased during the observation period
(−6.1%), and they more than doubled for the age group
≥85 years (+131.5%). During the same time period, no-
tification rates for the ≥85 years age group increased by
94.9% (47.2–92.0 per 100 000 population) and for the 5–9
years age group by 30.7% (55.3–72.3 per 100 000 popu-
lation) [2]. It was found that adults and the elderly suf-
fered increasingly more frequently from campylobacterio-
sis; this could be related to the frequent use of proton pump
inhibitors and comorbidities in these age groups [2, 26,
27]. Others have also observed increasing test numbers
among the elderly and related it to changes (increases) in
healthcare-seeking and physicians’ testing behaviour [14,
18, 24]. Additionally, the Swiss population aged ≥85 years
increased by 29% from 2003 to 2012, which probably also
contributed to the observed increase in test numbers [28].
Salmonella notification rates and annual sex-specific posi-
tivity rates showed similar decreasing trends. The strongest
decreases in age-specific annual Salmonella positivity
rates were observed for the age groups 10–14 years and
≥85 years (−64.8% and −75.0%, respectively). At the same
time, notification rates dropped by 55.4% (39.2–17.5 per
100 000 population) for the 10–14 year age group and
by 55.6% (23.9–10.6 per 100 000 population) for the ≥85
years group. It appears, therefore, that these decreases are
true epidemiological trends. Age-specific Salmonella pos-
itivity rates tended to be slightly higher for males but did
not remarkably differ between sexes. Similar observations
have been made for corresponding NNSID data [2].
The increasing trend in Campylobacter positivity rates was
similar for males and females. Also, male and female no-
tification rates to the NNSID likewise increased during
this time [2]. Both positivity rates and notification rates
for Campylobacter were higher among males than among
females in nearly all age groups. Higher positivity rates
for males have also been observed by others [18]. Higher
stool sampling rates have been reported for male patients
in Canada [18] and for female patients in Wales [14]. Sex-
specific differences in healthcare seeking or in risk expo-
sures could account for this observation.
Seasonality of positivity rates and notification rates
Monthly and weekly Campylobacter and Salmonella pos-
itivity rates showed seasonal trends corresponding to the
NNSID notification rates, which peaked during the sum-
mer months and, for Campylobacter, also at the beginning
of the year [2]. Summer peaks of Campylobacter and Sal-
monella positivity rates have also been described previ-
ously [18]. Monthly and weekly test numbers also peak in
summer. The seasonal variation of test numbers could in-
dicate seasonality of acute gastroenteritis, a temporal vari-
ation in the medical care-seeking behaviour of affected in-
dividuals and in the proportion of patients being tested.
For instance, returning travellers are more likely to under-
go stool diagnostics [24, 25, 29], leading to increased test
numbers during the public school holiday season in the
summer. The combination of high test numbers and high
positivity rates in summer and autumn generates the ob-
served peak in case numbers in the NNSID [2].
Peaks of Campylobacter and Salmonella notification rates
during summer months are observed in most European
countries [1, 2, 27, 30, 31]. The prevalence of Campy-
lobacter in broiler flocks and the contamination of chicken
meat with Campylobacter at retail are higher during sum-
mer months than during the rest of the year [31–34]. This
probably explains the observed seasonality as poultry meat
from broilers is the main source of Campylobacter infec-
tions in Switzerland [35–37]. However, it seems that the
summer peak is not caused by a single common source of
infection and is more likely driven by multiple sources of
animal and environmental exposures and climatic condi-
tions [27, 31, 38, 39]. An additional reason for the summer
peak in Switzerland and parts of the EU could be related
to the culture of barbequing during summer, which pro-
vides multiple occasions for disease transmission through
undercooking of and cross-contamination by poultry and
red meat [40–43]. Travel abroad is a known risk factor for
contracting campylobacteriosis [42–45] – also in Switzer-
land [46, 47] – and a large proportion of notified Salmonel-
la infections in Switzerland is travel-related [48]. Hence,
travelling probably contributes to the observed seasonality
of campylobacteriosis and salmonellosis test numbers and
case notifications in Switzerland.
The highest weekly positivity rate for Campylobacter was
found in calendar week 1 when test numbers were lowest.
Notification rates of campylobacteriosis in Switzerland
show a strong annual increase over Christmas and New
Year (“winter peak”). A similar peak in notification data at
the beginning of January has also been observed in Ger-
many [30] and in the Campylobacter surveillance data of
The European Surveillance System [1]. In Switzerland, the
major driver for the winter peak is frequent consumption
of meat fondue at festive occasions around this time, espe-
cially if it includes chicken meat [47]. The low test num-
bers over the festive season in December and January are
probably related to a different healthcare-seeking behav-
iour and restricted access to healthcare services during the
holiday period. Therefore, the winter peak in Campylobac-
ter notification rates is probably attenuated and does not
reveal the full magnitude of the problem.
Strengths and limitations
In Switzerland, private diagnostic laboratories operate on
a regional or national level and predominantly serve the
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practices of general practitioners and medical specialists.
The study did not consider hospital-based laboratories as
their patient profile generally differs from the patient pro-
file in private practices at the primary care level. Hos-
pitalised patients are likely to be more severely affected
by acute gastroenteritis and to undergo more extensive
diagnostic testing. Hence, their pre-test probability for a
positive Campylobacter or Salmonella test result is dif-
ferent from that of patients consulting at primary care prac-
tices [18]. The catchment population of the participating
laboratories is not known. Therefore, it was not possible
to describe the catchment population, adjust for potential
changes therein or to estimate any population-based indi-
cators like stool sampling rates. Similarly, we could not as-
sess how well the data of the five participating laboratories
represent the whole tested population in Switzerland, giv-
en the latter is not known. We could only assess the repre-
sentativeness of the patient population by comparing “our”
positively tested patients with all notified cases (and hence,
supposedly, all positively tested patients in Switzerland;
table 1 and table 2). From this comparison we conclude
that estimated positivity rates are likely to represent accu-
rately the epidemiological trends and situation in Switzer-
land as median age and the sex-ratio of cases identified
in participating laboratories and in cases from the NNSID
were comparable.
Conclusions
The study results support the assertion that the increase in
notification rates of campylobacteriosis and the decrease
in notification rates of salmonellosis are epidemiological
trends in the population. These trends cannot be solely ex-
plained by changing test numbers. Still, we believe it is
important to continuously assess test numbers or positivity
rates to note changes in stool testing frequency that could
lead to changes in case numbers seen in the notification
system. This becomes especially important in the light of
the increasing use of multiplex PCR panels where multiple
pathogens are tested simultaneously and, hence, test num-
bers can change substantially [49]. The annual collection
of test numbers of selected notifiable diseases as stipulated
under the newly enforced Swiss Epidemics Act will allow
for continuous assessment of positivity rates in the future.
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Appendix 1
Supplementary data
Table S1: Predictors for a positive Campylobacter stool test, Switzer-
land, 2003–2012.
N* Adj. OR† 95% CI‡ p-value§
Sex 135 122 <0.01
Female 74 006 1
Male 61 116 1.53 1.47–1.59
Age group 135 122 <0.01
<5 years 10 196 0.53 0.49–0.58
5–9 years 5137 0.71 0.64–0.79
10–14 years 3843 0.89 0.80–0.99
15–19 years 6362 1.32 1.23–1.43
20–24 years 9810 1.26 1.18–1.35
25–44 years 37 693 1
45–64 years 32 147 0.85 0.81–0.89
65–84 years 24 712 0.52 0.49–0.55
≥85 years 5222 0.31 0.26–0.36
Laboratory 135 122 <0.01
A 18 836 0.93 0.88–0.99
B 17 687 0.76 0.71–0.81
C 19 860 0.92 0.79–1.07
D 33 751 0.95 0.89–1.02
E 44 988 1
Greater region 135 122 <0.01
Lake Geneva region 3644 0.84 0.75–0.95
Espace Mittelland 32 912 1
Northwestern Switzer-
land
28 711 0.83 0.78–0.88
Zurich 29 472 0.73 0.68–0.79
Eastern Switzerland 14 931 0.93 0.86–1.00
Central Switzerland 4504 0.90 0.81–1.00
Ticino 20 948 0.44 0.38–0.52
Test year 135 122 <0.01
2003 11 674 0.68 0.62–0.73
2004 11 209 0.69 0.64–0.76
2005 11 077 0.72 0.66–0.78
2006 11 692 0.77 0.71–0.84
2007 12 481 0.85 0.79–0.92
2008 14 294 1.00 0.93–1.07
2009 14 685 0.98 0.91–1.05
2010 14 643 0.85 0.79–0.92
2011 15 726 0.97 0.91–1.04
2012 17 641 1
* Number of records † Adjusted odds ratio: adjusted for sex, age group,
laboratory, greater region and year of test ‡ 95% confidence interval §
p-value from likelihood ratio test
Table S2: Seasonality of a positive Campylobacter stool test by test
month, Switzerland, 2003–2012.
N* Adj. OR† 95% CI‡ p-value§
Sex 135 122 <0.01
Female 74 006 1
Male 61 116 1.53 1.47–1.59
Age group 135 122 <0.01
<5 years 10 196 0.54 0.50–0.59
5–9 years 5137 0.72 0.65–0.80
10–14 years 3843 0.90 0.81–1.00
15–19 years 6362 1.31 1.22–1.42
20–24 years 9810 1.25 1.17–1.34
25–44 years 37 693 1
45–64 years 32 147 0.85 0.81–0.89
65–84 years 24 712 0.53 0.49–0.56
≥85 years 5222 0.32 0.27–0.37
Laboratory 135 122 <0.01
A 18 836 0.92 0.87–0.98
B 17 687 0.76 0.71–0.81
C 19 860 0.90 0.77–1.04
D 33 751 0.94 0.89–1.01
E 44 988 1
Greater region 135 122 <0.01
Lake Geneva region 3644 0.84 0.75–0.95
Espace Mittelland 32 912 1
Northwestern Switzer-
land
28 711 0.84 0.79–0.89
Zurich 29 472 0.74 0.68–0.80
Eastern Switzerland 14 931 0.93 0.87–1.00
Central Switzerland 4504 0.90 0.81–1.00
Ticino 20 948 0.46 0.39–0.53
Test month 135 122 <0.01
January 10 502 0.98 0.89–1.08
February 9311 0.55 0.49–0.61
March 10 654 0.64 0.57–0.70
April 9659 0.74 0.67–0.82
May 10 691 1
June 11 607 1.38 1.26–1.50
July 11 730 1.52 1.40–1.65
August 13 991 1.23 1.13–1.34
September 13 126 0.98 0.90–1.07
October 11 766 1.03 0.95–1.13
November 11 552 0.93 0.85–1.02
December 10 533 1.02 0.93–1.12
Test year (random ef-
fect)
135 122 <0.01
* Number of records † Adjusted odds ratio: adjusted for sex, age group,
laboratory, greater region and year of test ‡ 95% confidence interval §
p-value from likelihood ratio test
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Table S3: Predictors for a positive Salmonella stool test, Switzerland,
2003–2012.
N* Adj. OR† 95% CI‡ p-value§
Sex 136 997 <0.01
Female 74 374 1
Male 62 623 1.30 1.21–1.40
Age group 136 997 <0.01
<5 years 10 287 3.24 2.88–3.66
5-9 years 5179 3.19 2.75–3.70
10–14 years 3845 3.17 2.68–3.74
15–19 years 6464 1.92 1.62–2.26
20–24 years 10 159 1.30 1.11–1.53
25–44 years 38 947 1
45–64 years 32 609 1.04 0.93–1.17
65–84 years 24 360 0.67 0.58–0.78
≥85 years 5147 0.38 0.27–0.55
Laboratory 136 997 <0.01
A 20 452 1.30 1.14–1.47
B 17 658 1.29 1.10–1.51
C 19 557 1.85 1.43–2.40
D 34 333 1.09 0.94–1.26
E 44 997 1
Greater region 136 997 0.13
Lake Geneva region 3643 1.12 0.87–1.46
Espace Mittelland 32 851 1
Northwestern Switzer-
land
28 889 0.87 0.75–1.00
Zurich 29 651 0.90 0.75–1.08
Eastern Switzerland 16 658 0.97 0.82–1.14
Central Switzerland 4595 0.78 0.61–1.00
Ticino 20 710 0.86 0.65–1.13
Test year 136 997 <0.01
2003 11 842 1.85 1.56–2.19
2004 11 342 1.70 1.43–2.02
2005 11 116 1.72 1.45–2.05
2006 11 741 1.69 1.42–2.01
2007 12 750 1.72 1.45–2.04
2008 14 485 1.61 1.36–1.90
2009 14 963 1.06 0.88–1.27
2010 14 910 1.06 0.88–1.28
2011 16 006 1.25 1.05–1.49
2012 17 842 1
* Number of records † Adjusted odds ratio: adjusted for sex, age group,
laboratory, greater region and year of test ‡ 95% confidence interval §
p-value from likelihood ratio test
Table S4: Seasonality of a positive Salmonella stool test by test
month, Switzerland, 2003–2012.
N* Adj. OR† 95% CI‡ p-value§
Sex 136 997 <0.01
Female 74 374 1
Male 62 623 1.30 1.20–1.40
Age group 136 997 <0.01
<5 years 10 287 3.38 3.00–3.81
5–9 years 5179 3.32 2.86–3.85
10–14 years 3845 3.21 2.71–3.79
15–19 years 6464 1.90 1.61–2.25
20–24 years 10 159 1.29 1.10–1.52
25–44 years 38 947 1
45–64 years 32 609 1.05 0.94–1.18
65–84 years 24 360 0.69 0.59–0.80
≥85 years 5147 0.40 0.28–0.57
Laboratory 136 997 <0.01
A 20 452 1.25 1.10–1.42
B 17 658 1.29 1.10–1.51
C 19 557 1.83 1.41–2.36
D 34 333 1.07 0.93–1.24
E 44 997 1
Greater region 136 997 0.18
Lake Geneva region 3643 1.11 0.86–1.44
Espace Mittelland 32 851 1
Northwestern Switzer-
land
28 889 0.87 0.76–1.01
Zurich 29 651 0.91 0.76–1.09
Eastern Switzerland 16 658 0.97 0.82–1.14
Central Switzerland 4595 0.78 0.61–1.00
Ticino 20 710 0.91 0.70–1.20
Test month 136 997 <0.01
January 10 522 0.72 0.59–0.89
February 9358 0.57 0.46–0.72
March 10 700 0.55 0.44–0.68
April 9669 0.73 0.59–0.90
May 10 678 0.89 0.73–1.08
June 11 696 1.13 0.94–1.36
July 11 831 1.33 1.11–1.58
August 14 525 1.44 1.23–1.70
September 13 551 1.29 1.09–1.53
October 12 042 1.61 1.36–1.90
November 11 612 1
December 10 813 0.74 0.60–0.91
Test year (random ef-
fect)
136 997 <0.01
* Number of records † Adjusted odds ratio: adjusted for sex, age group,
laboratory, greater region and year of test ‡ 95% confidence interval §
p-value from likelihood ratio test
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Figure S1: Campylobacter and Salmonella positivity rates strati-
fied by laboratory (and standardised for age and sex).
Figure S2: Annual Campylobacter and Salmonella positivity rates
standardised for age and sex in relation to the crude, non-stan-
dardised positivity rates calculated from raw data from all eight lab-
oratories included in the study, 2003–2012, Switzerland.
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